On February 17, 2026 Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), reported that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company’s presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2, and the webcast may be viewed here.
In addition to the presentation, management will be available for one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website. A replay will be available following the live event and will be archived for a limited time.
(Press release, Pasithea Therapeutics, FEB 17, 2026, View Source [SID1234662717])